« Back

AVI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference

10/19/10 8:35 AM EDT

BOTHELL, WA, Oct 19, 2010 (MARKETWIRE via COMTEX) --

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the 17th Annual NewsMakers in the Biotech Industry Conference in New York City on Friday, October 22 at 9:30 a.m. Eastern Time. J. David Boyle II, AVI's Interim President and Chief Executive Officer, and Chief Financial Officer, will provide a company overview.

The conference presentation will be webcast live under the events section of AVI's website at www.avibio.com, and will be archived there following the presentation. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About BioCentury NewsMakers In The Biotech Industry Conference

BioCentury is recognized as the essential provider of independent, informed business intelligence that regularly affects decisions made by bio-industry leaders and investors throughout the world. The 17th Annual NewsMakers in the Biotech Industry Conference, presented by BioCentury and Thomas Reuters, anticipates the news by featuring companies with major product and earnings events that promise to be key to the next upswing. The objective of NewsMakers is to stimulate interest in a hand-picked group of public biotech companies with corporate and regulatory milestones into 2011 and beyond. NewsMakers is recognized as the industry's key venue for companies to take their story to Wall Street each Fall. NewsMakers is an opportunity -- in a single day -- for the investment and pharma business development communities to assess the prospects for biotech stocks and to compare notes with key members of the institutional investment and analyst communities and pharma business development executives.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, we are able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, our technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging our highly differentiated RNA antisense-based technology platform, we have built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses. For more information, visit www.avibio.com.

SOURCE: AVI BioPharma, Inc. 


  
      






  


  
                                                                    

                                                                
                                                                
                                                                                                                                    

                                                                    
 

                                                                    
  
    
      
              
            
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.